Literature DB >> 7510693

Elimination of a major inhibitor epitope in factor VIII.

I M Lubin1, J F Healey, D Scandella, M S Runge, P Lollar.   

Abstract

The A2 and C2 domains of human blood coagulation factor VIII (fVIII) contain the epitopes targeted by most inhibitory allo- and autoantibodies. Human inhibitors usually display limited or no reaction with porcine fVIII. We constructed an active, recombinant hybrid human/porcine fVIII molecule by replacing the putative human fVIII A2 domain epitope with the homologous porcine sequence. The hybrid retained full activity in the presence of antibodies with specificity restricted to the human A2 epitope. In contrast, the hybrid was neutralized by an anti-C2 antibody. These findings provide a basis for fine epitope mapping and for therapy of the inhibitor patient.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510693

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.

Authors:  Ruth A Ettinger; Joseph A Liberman; Devi Gunasekera; Komal Puranik; Eddie A James; Arthur R Thompson; Kathleen P Pratt
Journal:  Blood Adv       Date:  2018-02-27

3.  Reduced antibody response to streptavidin through site-directed mutagenesis.

Authors:  D L Meyer; J Schultz; Y Lin; A Henry; J Sanderson; J M Jackson; S Goshorn; A R Rees; S S Graves
Journal:  Protein Sci       Date:  2001-03       Impact factor: 6.725

Review 4.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

5.  The diversity of the immune response to the A2 domain of human factor VIII.

Authors:  Rebecca C Markovitz; John F Healey; Ernest T Parker; Shannon L Meeks; Pete Lollar
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

6.  High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.

Authors:  Phuong-Cac T Nguyen; Kenneth B Lewis; Ruth A Ettinger; Jason T Schuman; Jasper C Lin; John F Healey; Shannon L Meeks; Pete Lollar; Kathleen P Pratt
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

Review 7.  Engineering less immunogenic and antigenic FVIII proteins.

Authors:  Kathleen P Pratt
Journal:  Cell Immunol       Date:  2015-11-02       Impact factor: 4.868

8.  Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.

Authors:  Jasper C Lin; Ruth A Ettinger; Jason T Schuman; Ai-Hong Zhang; Muhammad Wamiq-Adhami; Phuong-Cac T Nguyen; Shelley M Nakaya-Fletcher; Komal Puranik; Arthur R Thompson; Kathleen P Pratt
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

9.  Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity.

Authors:  Patricia E Zerra; Ernest T Parker; Wallace Hunter Baldwin; John F Healey; Seema R Patel; James W McCoy; Courtney Cox; Sean R Stowell; Shannon L Meeks
Journal:  Biomedicines       Date:  2022-07-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.